ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy.

Authors: Jason Westin, Gary Simmons, Nancy L. Bartlett, Houston Holmes, Matthew Matasar, Habte Aragaw Yimer, Mitul Gandhi, Jeff Porter Sharman, Ran Reshef, Akil A. Merchant, Yuliya Linhares, Don A. Stevens, Alex Francisco Herrera, Frederick L. Locke, Amy Feng, Lynn Navale, Jennifer Tsai, John Brian Le Gall, John M. Burke,

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps7085

Source: Full article

---

Abstract

TPS7085